Rear Window
Imugene’s $2.3b valuation raises eyebrows
Tom RichardsonJournalistOne advantage of having a ridiculous 4.9 billion shares on issue is that you really can throw them around like confetti.
Consider an ASX biotech named Imugene. It has no revenue or products and is at the clinical trial stage, but reached an incredible $2.3 billion market-cap based on a 47¢ share price on Wednesday.
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Equity markets
Fetching latest articles